REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Reviva Pharmaceuticals Holdings, Inc. OTC:RVPH OTC (suspended from Nasdaq on May 14, 2026) Healthcare · Biotechnology
Mkt Cap $4.65M
EV -
SI 3.1%
Net Cash/Sh -
CLOSED · Nov 17 +1.30%$0.3550 CLOSED · Nov 17 Prev close $0.3504 +1.30%Close $0.3550 VOL 7K $ Vol $3K RVOL 0.22x
Mkt Cap $4.65M
EV -
VOL 7K sh
$ Vol $3K
RVOL 0.22×
SI 3.1%
Net Cash/Sh -
Press Release
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Reviva reported a Q3 2026 net loss of approximately $2.3 million, or $0.17 per share, down from $4.0 million, or $1.09 per share, a year earlier, with cash of $17.5 million at quarter end. The company expects FDA feedback in Q4 2026 on use of a new brilaroxazine formulation in the RECOVER-2 Phase 3 trial and a future schizophrenia NDA, followed by a Q1 2027 bioequivalence study and 1H 2027 RECOVER-2 enrollment start. Enrollment is explicitly subject to additional financing, and the company plans to apply for Nasdaq relisting in 1H 2027 after being relegated to OTCQB following a 1:20 reverse split.
• 5d ago AI analysis › Press Release
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Reviva Pharmaceuticals (OTCQB: RVPH) will present at the Lytham Partners Fall 2026 Investor Conference, with management's webcast scheduled for 12:30 PM ET on Tuesday, September 29, 2026, and a replay available afterward. Founder, President and CEO Laxminarayan Bhat will lead the presentation, and management will also participate in virtual one-on-one meetings with investors throughout the event.
• 1mo ago AI analysis › Press Release
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Reviva reported a Q2 2026 net loss of $2.4 million, or $0.19 per share, significantly narrowing from the $6.1 million loss in the prior year as operating expenses decreased. Cash position improved to $19.9 million as of June 30, 2026, up from $14.4 million at the end of 2025.
• 3mo ago AI analysis › Press Release
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Aspire Biopharma Holdings was listed as a presenting company at the recent Life Sciences Virtual Investor Forum hosted by Virtual Investor Conferences. The company's presentation materials are now available for on-demand viewing and will remain accessible for 90 days.
• 4mo ago AI analysis › Press Release
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Aspire Biopharma Holdings (ASBP) is scheduled to present at the upcoming Life Sciences Virtual Investor Forum on June 25, 2026, at 2:00 PM ET. The event is hosted by Virtual Investor Conferences and features a roster of life sciences companies, allowing investors to view presentations and schedule one-on-one meetings with management teams.
• 4mo ago AI analysis › Press Release
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
Reviva Pharmaceuticals announced that CEO Laxminarayan Bhat will present at the Life Sciences Investor Forum on June 24, 2026. Management is also available for one-on-one meetings on June 26 and June 30 to discuss the company's pipeline and strategy.
• 4mo ago AI analysis › Press Release
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Reviva Pharmaceuticals CEO Laxminarayan Bhat will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. The session is scheduled for 2:40-3:00 PM ET and will feature equity research analyst Jim Molloy.
• 6mo ago AI analysis › Press Release
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals reported a net loss of $3.2 million, or $0.46 per share, for the first quarter of 2026, compared to a net loss of $6.4 million, or $2.61 per share, in the same period last year. The company's cash and cash equivalents increased to $22.2 million as of March 31, 2026, from $14.4 million as of December 31, 2025. Reviva has filed a provisional patent application for a new form of brilaroxazine, aiming to extend patent life and commercial exclusivity through 2046. The company expects FDA feedback on this strategy in mid-2026.
• 6mo ago AI analysis › Press Release
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Reviva Pharmaceuticals announced that CEO Dr. Laxminarayan Bhat will participate in a fireside chat hosted by A.G.P. Equity Research on April 27, 2026. The discussion will focus on the clinical-stage candidate brilaroxazine, highlighting positive topline data from the Phase 3 RECOVER trial in schizophrenia and upcoming regulatory and IP milestones.
• 6mo ago AI analysis › Press Release ● Major
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
globenewswire.com • 7mo ago